Literature DB >> 15023181

'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.

A D Clark1, W C Gordon, I D Walker, R C Tait.   

Abstract

BACKGROUND AND OBJECTIVES: The aim of this retrospective study was to assess the effect of activated recombinant factor VII (rFVIIa) on the natural history of massive transfusion episodes.
MATERIALS AND METHODS: During 2002, outcome parameters were assessed in 50 patients transfused with more than 10 units of packed red cells. The effect of the addition of rFVIIa in 10 patients, with intractable bleeding, was then observed.
RESULTS: Overall mortality was 20% at 24 h and 34% at 7 days. Severe coagulopathy was confirmed as a serious negative prognostic factor and occurred in 42% of patients overall, but in 70% of rFVIIa-treated patients. Transient cessation or reduction of bleeding was noted in 60% of patients following rFVIIa infusion. However, 24-h and 7-day mortality rates were 40% and 70%, respectively, in this group.
CONCLUSIONS: Last-ditch rFVIIa therapy in patients resistant to conventional treatment did not rescue these patients or significantly alter outcomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023181     DOI: 10.1111/j.0042-9007.2004.00393.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  14 in total

1.  Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study.

Authors:  James D Cooper; Arthur K Ritchey
Journal:  Ther Adv Drug Saf       Date:  2016-10-20

2.  Futility Assessment of Recombinant Factor VII Activated for the Treatment of Hemorrhagic Shock Requiring Massive Transfusion.

Authors:  James C McMillen; Christy M Lawson; A Shaun Rowe
Journal:  Hosp Pharm       Date:  2013-10

Review 3.  An evaluation of eptacog alfa in nonhaemophiliac conditions.

Authors:  Gordon Mallarkey; Tim Brighton; Amanda Thomson; Karen Kaye; Paul Seale; Madlen Gazarian
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Role of factor VII in correcting dilutional coagulopathy and reducing re-operations for bleeding following non-traumatic major gastrointestinal and abdominal surgery.

Authors:  Thomas C Tsai; James H Rosing; Jeffrey A Norton
Journal:  J Gastrointest Surg       Date:  2010-06-02       Impact factor: 3.452

5.  Trauma care today, what's new?

Authors:  Ramesh Ramaiah; Andreas Grabinsky; Kelvin Williamson; Sanjay M Bhanankar
Journal:  Int J Crit Illn Inj Sci       Date:  2011-01

6.  Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding.

Authors:  P Eller; C Pechlaner; Cj Wiedermann
Journal:  Thromb J       Date:  2006-01-18

Review 7.  Pro/con debate: does recombinant factor VIIa have a role to play in the treatment of patients with acute nontraumatic hemorrhage?

Authors:  Paola Pieri; Deborah M Stein; Sandro Scarpelini; Sandro Rizoli
Journal:  Crit Care       Date:  2006-06-01       Impact factor: 9.097

8.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637

9.  Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding.

Authors:  Anna Conen; Maja Weisser; Dimitrios A Tsakiris; Martin Siegemund
Journal:  BMC Infect Dis       Date:  2007-04-26       Impact factor: 3.090

Review 10.  Recombinant activated factor VII (Novo7) in patients with ventricular assist devices: case report and review of the current literature.

Authors:  Daniel Heise; Anselm Bräuer; Michael Quintel
Journal:  J Cardiothorac Surg       Date:  2007-10-26       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.